Tofersen Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 100 mg/15 mL

Reference Brands: Qalsody (USA)

Category: Neurology

Tofersen is available in Injection and strengths such as 100 mg/15 mL. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Tofersen is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Tofersen can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Tofersen, marketed under the brand name Qalsody, is a novel antisense oligonucleotide therapy developed for the treatment of amyotrophic lateral sclerosis (ALS) in patients with confirmed superoxide dismutase 1 (SOD1) gene mutations. ALS is a progressive and fatal neurodegenerative disorder characterized by the loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. Tofersen received accelerated approval from the U.S. Food and Drug Administration in April 2023, marking a significant advancement in the treatment of genetically defined ALS.

Tofersen works by selectively binding to SOD1 messenger RNA (mRNA), promoting its degradation and thereby reducing the production of the toxic mutant SOD1 protein. Elevated levels of mutant SOD1 are believed to contribute directly to motor neuron damage and disease progression. By lowering SOD1 protein concentrations in the cerebrospinal fluid, tofersen targets the underlying molecular cause of SOD1-associated ALS rather than providing only symptomatic relief.

The medication is administered as an intrathecal injection under specialist supervision. Treatment requires careful patient selection, genetic confirmation of SOD1 mutation, and ongoing monitoring for potential adverse effects. Tofersen represents a precision medicine approach in neurodegenerative disease management and offers a targeted therapeutic option for a specific subgroup of ALS patients.